文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

接受依鲁替尼治疗的血液肿瘤患者因严重感染入住重症监护室:GRRR-OH 研究

Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en réanimation onco-hématologique (GRRR-OH) study.
PubMed 文献 · Ann Intensive Care · 2023-12-06
一句话结论依鲁替尼治疗患者因严重感染入 ICU 者预后差,ICU 病死率 29%、第 90 天病死率 55%,以急性呼吸衰竭为主,作者建议ICU医生系统筛查机会性病原体。

该多中心队列纳入2015年1月1日至2020年12月31日法国10个ICU收治的69例接受依鲁替尼治疗的血液肿瘤合并严重感染患者,中位用药至感染时间6.6[3-18]个月,侵袭性真菌感染占19%(13/69),急性呼吸衰竭占71%(49/69),41%(28/69)需机械通气。ICU病死率29%(20/69),第90天病死率55%(35/64);死亡者SOFA评分更高(7[5-11] vs 4[3-7],p=0.004)、更常接受机械通气(68% vs 31%,p=0.010)。与63例年龄及基础肿瘤匹配的历史化疗对照组相比,依鲁替尼组既往化疗线数更多、真菌和病毒感染率更高,但ICU病死率(27% vs 38%,p=0.254)和第90天病死率(52% vs 48%,p=0.785)相似。作者认为该类患者严重感染预后差,主要受初始器官衰竭影响,ICU医生应系统筛查机会性病原体。

要点

  • 依鲁替尼治疗患者因严重感染入ICU时,急性呼吸衰竭最常见(71%,49/69),41%(28/69)需机械通气。
  • 侵袭性真菌感染占严重感染的19%(13/69),其中侵袭性曲霉病9例(69%,9/13)、肺孢子菌肺炎3例(23%,3/13)、隐球菌病1例(8%,1/13)。
  • ICU病死率29%(20/69),第90天病死率55%(35/64);死亡者SOFA评分更高(7[5-11] vs 4[3-7],p=0.004),更常接受机械通气(68% vs 31%,p=0.010)。
  • 与年龄及基础肿瘤匹配的历史化疗对照组相比,依鲁替尼组真菌感染(21% vs 8%,p=0.001)和病毒感染(17% vs 5%,p=0.027)更多,但ICU病死率(27% vs 38%,p=0.254)和第90天病死率(52% vs 48%,p=0.785)无显著差异。
  • 作者建议ICU医生对这类免疫抑制人群系统筛查机会性病原体。

适用人群与场景

  • 接受依鲁替尼治疗的血液肿瘤(如慢性淋巴细胞白血病、多种非霍奇金淋巴瘤)患者,因严重感染入住ICU者。
  • 研究纳入2015年1月1日至2020年12月31日法国10个ICU收治的69例患者。

红旗征与不能漏的情况

  • 急性呼吸衰竭(71%,49/69)是需要ICU入住的主要器官损伤,41%(28/69)需机械通气。
  • 侵袭性真菌感染占19%(13/69),包括侵袭性曲霉病、肺孢子菌肺炎和隐球菌病,作者建议系统筛查机会性病原体。

研究设计与关键结果

  • 多中心队列研究:2015年1月1日至2020年12月31日法国10个ICU收治的69例接受依鲁替尼治疗的血液肿瘤合并严重感染患者。
  • 从依鲁替尼起始至感染的中位时间为6.6[3-18]个月。
  • 侵袭性真菌感染占19%(13/69),包括侵袭性曲霉病9例(69%,9/13)、肺孢子菌肺炎3例(23%,3/13)、隐球菌病1例(8%,1/13)。
  • 急性呼吸衰竭占71%(49/69),41%(28/69)需机械通气。
  • ICU病死率29%(20/69),第90天病死率55%(35/64)。
  • 与存活者相比,死亡者SOFA评分更高(7[5-11] vs 4[3-7],p=0.004),更常接受机械通气(68% vs 31%,p=0.010)。
  • 63例依鲁替尼治疗患者按年龄和基础肿瘤与63例接受传统化疗的历史队列对照匹配;依鲁替尼组既往化疗线数更多(2[1-2] vs 0[0-2],p<0.001),真菌感染率更高(21% vs 8%,p=0.001),病毒感染率更高(17% vs 5%,p=0.027);ICU病死率(27% vs 38%,p=0.254)和第90天病死率(52% vs 48%,p=0.785)两组相似。

证据类型、等级与局限

  • 证据类型:多中心队列研究(法国10个ICU)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,接受依鲁替尼治疗的患者发生需ICU入住的严重感染时预后差,主要受初始器官衰竭影响。
  • 作者建议ICU医生对这类免疫抑制人群系统筛查机会性病原体。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In the last decade, Ibrutinib has become the standard of care in the treatment of several lymphoproliferative diseases such as chronic lymphocytic leukemia (CLL) and several non-Hodgkin lymphoma. Beyond Bruton tyrosine kinase inhibition, Ibrutinib shows broad immunomodulatory effects that may promote the occurrence of infectious complications, including opportunistic infections. The infectious burden has been shown to vary by disease status, neutropenia, and prior therapy but data focusing on severe infections requiring intensive care unit (ICU) admission remain scarce. We sought to investigate features and outcomes of severe infections in a multicenter cohort of 69 patients receiving ibrutinib admitted to 10 French intensive care units (ICU) from 1 January 2015 to 31 December 2020.

RESULTS: Median time from ibrutinib initiation was 6.6 [3-18] months. Invasive fungal infections (IFI) accounted for 19% (n = 13/69) of severe infections, including 9 (69%; n = 9/13) invasive aspergillosis, 3 (23%; n = 3/13) Pneumocystis pneumonia, and 1 (8%; n = 1/13) cryptococcosis. Most common organ injury was acute respiratory failure (ARF) (71%; n = 49/69) and 41% (n = 28/69) of patients required mechanical ventilation. Twenty (29%; n = 20/69) patients died in the ICU while day-90 mortality reached 55% (n = 35/64). In comparison with survivors, decedents displayed more severe organ dysfunctions (SOFA 7 [5-11] vs. 4 [3-7], p = 0.004) and were more likely to undergo mechanical ventilation (68% vs. 31%, p = 0.010). Sixty-three ibrutinib-treated patients were matched based on age and underlying malignancy with 63 controls receiving conventional chemotherapy from an historic cohort. Despite a higher median number of prior chemotherapy lines (2 [1-2] vs. 0 [0-2]; p < 0.001) and higher rates of fungal [21% vs. 8%, p = 0.001] and viral [17% vs. 5%, p = 0.027] infections in patients receiving ibrutinib, ICU (27% vs. 38%, p = 0.254) and day-90 mortality (52% vs. 48%, p = 0.785) were similar between the two groups.

CONCLUSION: In ibrutinib-treated patients, severe infections requiring ICU admission were associated with a dismal prognosis, mostly impacted by initial organ failures. Opportunistic agents should be systematically screened by ICU clinicians in this immunocompromised population.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Baucher L, Lemiale V, Joseph A, et al. Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en réanimation onco-hématologique (GRRR-OH) study. Ann Intensive Care. 2023. PMID: 38055081. doi:10.1186/s13613-023-01219-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。